Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia
一项针对慢性粒细胞白血病患者的I期研究，评估了第三代BCR::ABL1酪氨酸激酶抑制剂vamotinib (PF-114)的疗效。
期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-025-06239-8
Turkina, Anna; Vinogradova, Olga; Lomaia, Elza; Shatokhina, Evgeniya; Shukhov, Oleg; Chelysheva, Ekaterina; Shikhbabaeva, Dzhariyat; Nemchenko, Irina; Petrova, Anna; Bykova, Anastasiya; Siordiya, Nadiya; Shuvaev, Vasily; Mikhailov, Ilya; Novikov, Fedor; Shulgina, Veronika; Hochhaus, Andreas; Ottmann, Oliver; Cortes, Jorge; Gale, Robert Peter; Chilov, Ghermes
